DiaSorin launches LIAISON® Mycoplasma pneumoniae IgG and IgM assays (available outside the US and Canada only)


DiaSorin announces the successful development of 2 new assays for detection of antibodies to Mycoplasma pneumoniae on the LIAISON® instrument: LIAISON®Mycoplasma pneumoniae IgG and LIAISON®Mycoplasma pneumoniae IgM.
Mycoplasma pneumoniae infection is responsible for 10-30% of cases of Community Acquired Pneumonia (CAP), and is most common in children aged 2-12, with 80% of adults being seropositive for IgG. However, severe complications have been reported such as tracheobronchitis, upper respiratory tract disease, asthma and a significant rate of hospitalisation, especially in the elderly. Furthermore, due to the lack of a cell wall, mycoplasmas do not respond to penicillins and other beta-lactams used for the treatment of bacterial pneumonia. Therefore, differential diagnosis of M. pneumoniae is crucial for effective patient management.
Serology is widely accepted as the method of choice in laboratory diagnostics - presence of IgM and/or a significant rise in IgG antibodies reliably provides evidence of current / recent M. pneumoniae infection. The technological advantages of the LIAISON® system and the quality of the reagents and antigen selection have been combined to create a new approach to Mycoplasma pneumoniae diagnosis.
LIAISON® Mycoplasma pneumoniae IgG uses recombinant peptide of the 170-kDa P1 adhesion protein of M. pneumoniae whereas the LIAISON® Mycoplasma pneumoniae IgM, in addition to the P1 antigen, also incorporates whole-cell lysate.
With the addition of the two new assays to the LIAISON® Infectious Disease menu, DiaSorin is now the first company to be able to offer assays for detection of IgG and IgM antibodies to Mycoplasma pneumoniae on a fully automated platform.